Loading...
•
Sep 30, 2024
Janux Q3 2024 Earnings Report
Reported financial results for the third quarter ended September 30, 2024, and provided a business update.
Key Takeaways
Janux Therapeutics reported a net loss of $28.1 million for the third quarter of 2024, with cash and cash equivalents and short-term investments totaling $658.0 million. The company is focused on enrolling participants in clinical trials for JANX007 and JANX008 and anticipates providing an update on the JANX007 program by year end.
Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors.
An update on JANX007 data and doses selected for expansion cohorts is anticipated in 2024.
Cash and cash equivalents and short-term investments totaled $658.0 million at the end of the third quarter 2024.
Net loss for the quarter ended September 30, 2024, was $28.1 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...